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the 72-hour period, without significant differences between 4°C 
and RT storage (29% and 20% initial values, respectively). T- 
cell content remained stable at both temperatures and in blood 
and BM HPC grafts during 3 days storage. A marked decline in 
the number of viable type 2 dendritic cell progenitors (DC2p) 
was seen in the first 24 hours in blood HPC grafts during stor- 
age at both 4°C and RT (27% and 24% and of initial values, 
respectively), while content of DC2p in BM HPC grafts 
remained stable up to 48 hours (60% and 70% initial values at 
4°C and RT, respectively). Conclusions: Storage at 4°C did not 
impair the content of viable CD34+ cells or T-cells in blood or 
BM ItPC grafts, and was superior to storage at RT in preserv- 
ing the overall viability of blood HPC grafts. DC2p are particu- 
larly sensitive to storage, and prolonged transit times may 
impact the content of these immuno-regulatory cells in trans- 
plants. 
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Viable CD34+ 50% 29% 29% ] 20q 
Viable CD3+ 51% 63% 77% ] 27% 
Viable DC2p 54% 31% 8% ! I1~ 
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OUTCOME OF PATIENTS TREATED WITH HIGH DOSE MELPHALAN 
WITH OR WITHOUT TBI FOLLOWED BY CD34 SELECTED STEM CELL 
RESCUE USING THE BAXTER ISOLEX 3001 
B'roun, E.R.; Sigmund, D.; Essell, J.; Tievne~, C. Jewish Hospital, 
Cincimmti, OH. 
We treated 24 patients with multiple myeloma with high dose 
melphalan +/- TBI using CD34 selection between 1/99 and 7/01. 
Patients were treated as part of initial therapy following 4 cycles of 
VAD in most cases. Mobilization was with either VP16/ 
cyclophosphamide (5) or cyclophosphamide (19) followed by G- 
CSF. Patients then underwent 20L apheresis on a COBE Spectra 
with a collection goal of 6.5 x 106 CD34+ cells/kg. CD34 selection 
with the BAXTER Isolex 300i was carried out on the pheresis 
product with 1.5 x 106 CD34+cells/kg stored as backmp. Patients 
underwent a median of 2 phereses (range 1-6) with a mean collec- 
tion of 24.1 x 10 6CD34+ cells/kg (range 6.9-57.8). Following 
selection, a mean of 10.4 x 106 CD34+ cells/kg were infused at 
time of transplant. Post infusion recovery of WBC to an ANC 
>500/uL occurred in a mean of 26.9d (range 13-7 l d) and platelets 
to >20, 000/uL at 79.3d (range 15-360d). 4 patients expired prior 
to recovery of platelets and one remains platelet ransfusion 
dependent 3 years post transplant. There was one early death due 
to aspiration pneumonia. Overall 10 pts have expired, cause of
death: progressive disease 6, pneumonia 2, sepsis 2. The remain- 
ing 14 pts are alive, 3 in relapse and 11 (46%) in remission. Nine 
patients have relapsed (38%). Mean follow-up for the entire 
group is 18.4 mos. For the 11 pts in remission the median time 
frmn transplant is 18 mos (14-41 mos). CD34 selection led to pro 
longed recovery of granulocytes and platelets. Longer follow-up is 
needed to assess the durability of the remissions. 
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ENGRAFTMENT AND PRODUCTION OF MESENCHYMAL COLONY 
FORMING CELLS (M-CFC) IN VITRO 
La Russa, ~:F.; Lee, M.; Price, S.; Sarah, H.; Mille1", A.; Rozm~s, M.; 
~Veiner, R. TULANE UNIVERSITY CANCER CENTER, NEW 
ORLEANS, L4. 
A 2-stage stromal cell culture system that supports production of 
early hematopoietic progenitor cells (LTCIC, CFU-BLAST) was 
evaluated tbr mesenchymal progenitor cells, M-CFC. Stage-1 was 
initiated by culturing female bone marrow low density" mononu- 
clear cells (LDMNC) for 2 weeks. At day 0, 2-week old female 
recipient stromal colonies were lethally irradiated (25Gy) to elimi- 
nate endogenous M-CFC(XX) and then seeded with 2.5X10 ~ 
LDMNC from male-donor bone marrow containing only 27+_3 
M-CFC(XY). Engraftment and subsequent production of male 
donor-derived M-CFC (XY) activity was measured weekly by sec- 
ondary plating of both non-adherent and adherent cell fractions 
derived from female-recipient stromal colonies that were initially 
seeded with male donor bone marrow LDMNC. Fluorescence in
situ-hybridization (FISH) with DNA probes DXZI from the X- 
chromosome centromere region and the DYZI from the Yql2 
region was performed on representative s condary M-CFC 
derived stromal colonies at each week. At week-1 there was >7X 
expansion of M-CFC(XY) activity in both adherent and non- 
adherent stromal cell fractions as compared to the original 27+3 
M-CFC(XW) added at day 0. Most of the M-CFC(XY) activity 
localized within the female recipient adherent stromal cell fraction 
contained 187+-17 M-CFC(XY)/plate and formed individual stro- 
mal colonies with surface area r nge: 4rome; <16 mm 2. In addition, 
there were 20+2 M-CFC(XY)/plate, that were more proliferative 
and formed larger colonies with surface area range: >16 ram-'; < 30 
mm~, and 10+-2 M-CFC(X~/plate with the highest proliferative 
potential forming colonies with surface area: >30 mm 2. At week-2, 
ahnost all of the M-CFC(XY) remained in direct-contact with the 
female recipient adherent stromal cell fraction and continued to
further expand to 490+50 M-CFC(XY)/plate. The plating effi- 
ciency of mesenchymal progenitor cells at 3-weeks was >90% with 
a yield of 1, 150+-150 M-CFC (XY) / plate, but their proliferative 
index was reduced to form smaller stromal ceil colonies with sur- 
face area 4mm-'; <16 nun 2, and 13,600+-770 stromal cell clusters 
(XY)/plate. These studies show" that lethally irradiated female 
recipient mesenchymal/stromal cell colonies upport the engraft- 
ment of pre-clonogenic mesenchymal stenrcells. 
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FLOW CYTOMETRIC ANALYSIS OF CELLULAR DIFFERENTIATION 
ARREST IN MYELODYSPLASTIC SYNDROME 
S,beJw~an, M.; Dicke, K.; Palmer, D. Stem Cell Lab, A'dington Cance'~" 
Center, Arlington, T2~ 
CD33 has been shown to be a marker for cellular immaturity at 
the promyelocyte l vel. One of the hematological findings in 
myelodysplastic syndrome (MDS) is cellular differentiation (mare- 
ration) arrest. The purpose of this study was to determine the 
diagnostic utility of flow cytometry in confirming the clinical find 
ings in MDS. Our study analyzed the percentage of CD33+ and 
CD 33 +/CD 11 c+ cells by flow cytometry in 18 patients clinically 
diagnosed with MDS. Controls consisted of 30 patients who were 
hematologically normal. Normal ranges for CD33+ and 
CD33+/CD11c+ were 19-41% and 58-80%, respectively. All 18 
MDS patients were found to have a percentage of CD33+ cells in 
excess of 41% (43-68%) and a percentage of CD33+/CDllc+ 
cells less than 58% (31-56%), clearly demonstrating anaccumula- 
tion of ceils at the promyelocyte l vel at the expense of mature 
cells, demonstrating maturation arrest. We also found a slight 
increase in CD34+/CD33+ cells (from 0.5% to 0.73 %), therefore 
a prelude for excess blast cells and the possible transformation f 
MDS into acute myelocytic leukemia (AML). We conclude that 
flow cytometry is a promising tool in assisting the clinician in 
diagnosing MDS and its progression. 
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MOBILIZATION OF PERIPHERAL BLOOD PROGENITOR CELLS (PBPC) 
WITH COMBINATION OF CYTORINES IN AUTOLOGOUS AND ALLO- 
GI:NEIC PEDIATRIC TRANSPLANT 
Guev~'a, J.A.; Mm'tinez, C.A.; Barrios, N.J. Pediatrics, Univer,'ity of 
Puel"to Rico Sc,%ol of MedMne, San J.an, Pue'~to Rico. 
Background:Clinical trials to mobilize PBPC for antologous 
and allogeneic harvesting prior to high dose chemotherapy / 
radiotherapy include chemotherapy, eytokines, or chemotherapy 
combined with cytokines. PBPC mobilized by G CSF or GM- 
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